756 related articles for article (PubMed ID: 20223784)
1. A behavioural Bayes approach to the determination of sample size for clinical trials considering efficacy and safety: imbalanced sample size in treatment groups.
Kikuchi T; Gittins J
Stat Methods Med Res; 2011 Aug; 20(4):389-400. PubMed ID: 20223784
[TBL] [Abstract][Full Text] [Related]
2. A behavioral Bayes method to determine the sample size of a clinical trial considering efficacy and safety.
Kikuchi T; Gittins J
Stat Med; 2009 Aug; 28(18):2293-306. PubMed ID: 19536745
[TBL] [Abstract][Full Text] [Related]
3. Optimal sample size determinations from an industry perspective based on the expected value of information.
Willan AR
Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
[TBL] [Abstract][Full Text] [Related]
4. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
5. A decision theoretic approach to sample size determination in clinical trials.
Gittins JC; Pezeshk H
J Biopharm Stat; 2002 Nov; 12(4):535-51. PubMed ID: 12477073
[TBL] [Abstract][Full Text] [Related]
6. Implementing a decision-theoretic design in clinical trials: why and how?
Palmer CR; Shahumyan H
Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
[TBL] [Abstract][Full Text] [Related]
7. A Bayesian cost-benefit approach to the determination of sample size in clinical trials.
Kikuchi T; Pezeshk H; Gittins J
Stat Med; 2008 Jan; 27(1):68-82. PubMed ID: 17566967
[TBL] [Abstract][Full Text] [Related]
8. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods.
Willan A; Kowgier M
Clin Trials; 2008; 5(4):289-300. PubMed ID: 18697843
[TBL] [Abstract][Full Text] [Related]
9. The choice of sample size: a mixed Bayesian / frequentist approach.
Pezeshk H; Nematollahi N; Maroufy V; Gittins J
Stat Methods Med Res; 2009 Apr; 18(2):183-94. PubMed ID: 18445695
[TBL] [Abstract][Full Text] [Related]
10. The value of information and optimal clinical trial design.
Willan AR; Pinto EM
Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619
[TBL] [Abstract][Full Text] [Related]
11. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
[TBL] [Abstract][Full Text] [Related]
12. Sample size determination for phase II clinical trials based on Bayesian decision theory.
Stallard N
Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
[TBL] [Abstract][Full Text] [Related]
13. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
Chen MH; Willan AR
Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
[TBL] [Abstract][Full Text] [Related]
14. Bayesian adaptive D-optimal design with delayed responses.
Li J; Fu H
J Biopharm Stat; 2013 May; 23(3):559-68. PubMed ID: 23611195
[TBL] [Abstract][Full Text] [Related]
15. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
16. Optimal choice of the number of treatments to be included in a clinical trial.
Stallard N; Posch M; Friede T; Koenig F; Brannath W
Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083
[TBL] [Abstract][Full Text] [Related]
17. The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.
Nixon RM; O'Hagan A; Oakley J; Madan J; Stevens JW; Bansback N; Brennan A
Pharm Stat; 2009; 8(4):371-89. PubMed ID: 19340851
[TBL] [Abstract][Full Text] [Related]
18. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
19. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs.
Patel NR; Ankolekar S
Stat Med; 2007 Nov; 26(27):4976-88. PubMed ID: 17579924
[TBL] [Abstract][Full Text] [Related]
20. A hybrid Bayesian-frequentist approach to evaluate clinical trial designs for tests of superiority and non-inferiority.
Shao Y; Mukhi V; Goldberg JD
Stat Med; 2008 Feb; 27(4):504-19. PubMed ID: 17854052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]